Ependymoma is a type of brain or spinal cord tumor that develops from ependymal cells that line the ventricles and canal of the central nervous system. Ependymoma tumors are often treated through surgery, radiation therapy, and chemotherapy. However, emerging new drugs for the treatment of ependymoma offer more targeted therapy and improved prognosis. Drugs being developed include tazemetostat, larotrectinib, and selumetinib.
The global Ependymoma Drug Market is estimated to be valued at US$ 172.64 billion in 2023 and is expected to exhibit a CAGR of 7.7% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: The opportunity of emerging new drugs for ependymoma treatment provides immense growth prospects for the ependymoma drug market. Drugs currently under development offer more targeted approach to inhibit specific molecular pathways driving tumor growth. For instance, tazemetostat being developed by Epizyme is a first-in-class EZH2 inhibitor drug. EZH2 is a histone methyltransferase enzyme implicated in the progression of several cancers including ependymoma. In clinical trials, tazemetostat has shown promising antitumor activity and an acceptable safety profile for the treatment of recurrent or refractory ependymoma. Similarly, larotrectinib and selumetinib target the NTRK and RAS/MAPK pathways respectively. Their approval will help address the unmet need of improved and personalized treatment options and drive the demand for ependymoma drugs over the forecast period. Porter's Analysis Threat of new entrants: The threat of new entrants in the Ependymoma Drug Market is low as significant capital investment and research is required to develop new drugs. Bargaining power of buyers: The bargaining power of buyers is high due to the availability of substitutes. Bargaining power of suppliers: The bargaining power of suppliers is moderate as alternative suppliers are available. Threat of new substitutes: The threat of new substitutes is high as many drugs are being researched for the treatment of ependymoma. Competitive rivalry: The competitive rivalry in the market is high due to presence of many established players. SWOT Analysis Strengths: Availability of various treatment options and increasing research and development activities. Weaknesses: High costs associated with drug development and less awareness about the disease. Opportunities: Growing investment in drug development and unmet needs. Threats: Stringent regulations and alternative treatment options. Key Takeaways The Global Ependymoma Drug Market Growth is expected to witness high during the forecast period of 2024 to 2031. The global Ependymoma Drug Market is estimated to be valued at US$ 172.64 billion in 2023 and is expected to exhibit a CAGR of 7.7% over the forecast period 2024 to 2031. Regional analysis shows that North America holds the largest share in the market due to growing research and development activities as well as presence of key players in the region. Europe is the second largest market. Asia Pacific is expected to exhibit the fastest growth over the forecast period owing to increasing healthcare investments in countries such as China and India. Key players operating in the Ependymoma Drug Market are Thermo Fisher Scientific, QIAGEN, PROMEGA, F. Hoffmann-La Roche, Bio-Rad Laboratories, Agilent Technologies, among others. Thermo Fisher Scientific is one of the leading suppliers of research reagents and instruments. Get more insights on Ependymoma Drug Market
0 Comments
Leave a Reply. |
|